Advertisement Bio-Matrix and Vibragene sign letter of intent for genetic testing - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bio-Matrix and Vibragene sign letter of intent for genetic testing

Bio-Matrix Scientific Group has entered into a letter of intent with Vibragene, an anti-aging and genetic analysis company.

Pursuant to the letter of intent, it is proposed that Bio-Matrix will perform human DNA genetic testing for biomarkers that may play important roles in disease development. Vibragene anticipates sending 100,000 specimens to Bio-Matrix for testing during the next 12 months. Additionally, Bio-Matrix will supply DNA testing kits to Vibragene for the collection of DNA specimens.

Completion of the proposed agreement is subject to a number of conditions, including but not limited to, the establishment of pricing acceptable to the parties.